Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours.

被引：3

作者：

Ahnert, Jordi Rodon

Garratt, Chris

Laapas, Kaisa

Leskinen, Hanna

Bjorklund, Harry

Ruck, Angela

Peltola, Katriina

Azaro, Analia

Castanon-Alvarez, Eduardo

Massard, Christophe

Bono, Petri

机构：

[1] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain

[2] Univ Autonoma Barcelona, Barcelona, Spain

[3] Orion Pharma, Nottingham, England

[4] Orion Pharma, Espoo, Finland

[5] Orion Corp, Espoo, Finland

[6] Orion Corp, Orion Pharma, Turku, Finland

[7] Orion Corp, Orion Pharma, Nottingham, England

[8] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland

[9] Vall dHebron Inst Oncol, Barcelona, Spain

[10] Inst Gustave Roussy, Villejuif, France

[11] Gustave Roussy Canc Ctr, Villejuif, France

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.2576

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2576

引用

页数：2